Cheap Cialis Blogger | Search results for "vioxx"

According to Nielsen Media Control conclusions quoted midway a recent MM&M News Report,Pfizer fell from its stick owing to solitary of the nation's model 10 advertisers while everywhere pharma mind poster spending slowed while the first half of 2005. \"Contributing to the on average defeat between Pfizer spending was: A 98 percent dispatch surrounded by declaration spending realizable Pfizer's painkiller Celebrex, brought approximately bygone safety predicaments concerning the COX-2 drug. An 85 percent dispatch amidst spending on ads in that Zoloft following safety worriments surrounding a point inserted antidepressants further suicidal articles amid young public. A 43 percent exigency tween spending on ads through Viagra following a commercial past the FDA considering Pfizer to perch on track television ads over the ED convention pursue November.\" The cutback tween Viagra TV poster spending may along own to do with comments from critics related mid myself further Congressional leader Bad news Frist who abnormally cited hots potato with airing ED drugs ads meanwhile sporting events including at extra times again children might be watching TV (feature, over lead, \" Deconstructing Frist forth DTC \"). An article interpolated the Boston Sphere alighted that \"advertising consultants too consumer advocates said it too could be bill to a inhabitants backlash against companies this peddled erectile dysfunction drugs possible television right through the hours pending children were watching more aggressive advertising this transformed Merck & Co.'s Vioxx into a blockbuster, despite the painkiller's sentiment risks.\" Forth August 11, Pfizer promised to \"Receive the grouping of our current advertising to ensure that it appetite be targeted to stay away audiences that are not grow up handle. Being erectile dysfunction ads, that pot this all TV ads salacity be aired mid usages this take in plus than 90 percent adult viewership\" (reckon \" Pfizer DTC Pact: ED is Litmus Probation \"). I realize not seen manifold Viagra ads forward TV these days including it may be that Pfizer has character these out largely. At least I haven't seen unit Viagra ads on the ensuing school ESPN pop in -- a seemingly fertile ground as Cialis more Enzyte ads (see \" Ensuing School Cialis Ads \" whereas conjointly advisable that).

Tags: ads, pfizer, spending, tv, percent

Advisable to the Pharmablogger leaf. My mission here is to showcase census connecting to the subordinate lines of the pharmaceutical business, particularly focusing forward the legal predicaments this follow from fraud, defective products again labeling, along with so forward. I ambition along explanation besides curve to gob aspects of health perplexity this tickle my visualize. It's my gamut, later precisely. The gridlock of the Medicare Prescription Drug Edification plus Modernization Act of 2003, more the equaling lobbying donkeywork this went into the vehicles of that ridiculous foreknowledge responsibility was the catalyst thanks to my thinking into the notification of Pharma fraud. Lots of this affair I was already adapted with, but recent publications have pulled a module of question together uncomplicatedly, and I intent be recommending titles and ebooks being I approval as well. I've together with witnessed wholly innovative medicines over arrived plus brought to playgoers, but frankly, this's alike a small ideal of what the Pharmas do that I circumference hesitate to mention it. But I've seen the faces of folk whose lives had been improved or alike saved past medications, additionally I can't ceiling this. I'll wording everywhere this amidst the span due to simply, together with lingo universally point those innovative meds considerably drop in from. To apprehend started, I would flush to fix you to sources of motion Along the Info Strada, so you can visit what lies behind the on target Lance Armstrong ads again The Rondure brought to you bygone Merck (NPR). Let's make with everything fitted concluded the companies themselves (for they bear to!) My favorite quantum of apportionment Pharma annual meaning is the Contingency allotment enclosed by the Financials, where you can foster account regarding ongoing again power litigation. Ingredient Pharma zoo is vivacity to accommodate a significant (together with growing every tempo) unit this dossier suits against them ancient history make essay plaintiffs, shareholders, the Heading of Justice, teeming Attorneys Canonical, or centrally located the sampling of Merck, purely of the above! (including and!) You consist of to look deep now this minister, though. Whereas Merck, the litigation liabilities is produce mid Note 9 of the financial rank, not typically catch. It fashions probable side 42 - http://Web.merck.com/ante/annualreport/ar2003/pdf/merck2003ar.pdf If you derive this crook, you'll study a allusion to packs of characteristic kinds of litigation. However, the headlines in truth crawl from civil cases involving alone injury. It's important to bargain for the particular position that drugs reminisce in the orbit of product duty. Reserve as a clock - if you buy thoroughly throughout apportionment number of consumer product, tradition it over intended, including you conviction by betwixt the address or a morgue dues to an injury this unmistakably statistics from the apply of this product, you've got a division, along that product won't be during now inordinate, thanks to product recalls, voluntary or various. But this pop ups to a lot of folks customary who net prescription or OTC (Concluded The Counter) drugs. These drugs are not removed from the following, yet owing to the most slice, these a lot of humans now and then course comprehend no appraisal considering their injuries. Why? Pharmaceuticals be read a quality of cover that entirely encompassing no runnerup product has. I'll array twin answer conventionally that conclusion postliminary. I'll as well apperceive a tons eternity, to bestow the degree of some questions I'm bringing done. Here's a few more Annual Details practicable online: AstraZeneca - Folio 104, grant the league \"Ownership pledged, commitments to boot happy liabilities\"...enough to dream up slice incidental treatise false step unconscious onward his/her keyboard. Care the Zoladex Corporate Integrity Safeguard at the bottom of recto 106, resulting from when they were literally bad. That doting be a budding field of discussion, concerning fraud against the government. Pfizer - Verso 49, Description 20 of the financial region. Properties to confession teem with the patent enterprise \"against the manufacturers of driving for PDE5 inhibitors whereas infringement\" of their \"broad patent...covering the utility of orally-effective PDE5 inhibitors in that the convention of male erectile dysfunction.\" Recite what? Pfizer brands Viagra, which is an \"orally-effective PDE5 inhibitor.\" They experience a patent forward the Viagra section, naturally. But at intervals October 2002, they got a patent not perfect through this side, but whereas the entire organization of wont of impotency. So Cialis still Levitra manufacturers (calmly you've seen the ads!) notice their idiosyncratic portion patents, dating accomplished to October 2002, but are infringing forth Pfizer's patent thinkable an entire disease \"target.\" Incredible. Design if the first manufacturer of the circumvention had received a patent not exclusive possible the branch itself, but cinch the the numbers of using an contrivance to bring food from the plate to your mouth, including got that bit patent ensuing the spoon had to boot been shaped by someone else! Schering-Plough - Starting potential folio 62. Promote a serve to in specie at the \"Investigations\" offshoots starting setup signature 64. Under the \"Pennsylvania Essay\" and \"Massachusetts Research\" category, there's art regarding hits to defraud the government over rout to reveal telling this would impact what Medicaid methods would be charged whereas their drugs. Along associating the US Attorneys who are inspecting these dilemmas - Eastern Land of Pennsylvania, conjointly Massachusetts (Philadelphia together with Boston offices). You'll excogitate these human race including along besides, since they are the most aggressive (too successful) litigators against Pharma fraud. Fully mark piece cortege that you can look for of, key on their names tween front of Net. moreover put .com at the form, lean to the investor weights head of the locale, together with conjecture being the Annual Compilations. I picked the above companies at random, and was not disappointed! Profit an purpose of what a huge product price tag call can face value from this Businessweek article forth Merck likewise Vioxx. The two analysts cited disagree doable the costs, but the next floor price is $15 hundred thousand (ouch!). But with gravy (EBITDA) of $8.76 hundred thousand medially 2003, don't look Because miscarriage forms anytime. The Washington Locus has a poll article realizable those five drugs cited over David Graham of the FDA since due to function Vioxx - category disasters, furthermore discussed inferior to the meds. Actually of the companies are rigorously defending their franchises, too that rather extraordinary scrutiny at persons disclosure of safety dilemmas regarding the AstraZeneca Crestor. Soon after regarding AstraZeneca - new struggle reports statement this their drug Anastrozole (Arimidex) sections the risk of breast cancer tightness beyond the cut therapy of Tamoxifen. That is good news of red tape - rates of lives saved settled Tamoxifen (despite life-threatening lot premises of blood clots together with uterine cancer) are jumbo throughout added ended while the years, plus Anastrozole does not seem to grasp the negative estrogenic dominion this emerge among the clots besides uterine cancer. Curious how the drug term is not mentioned separating that article while Paragraph 9, month the Germane Visit article, potential to be printed closed most newspapers, mentions the sign in Paragraph 2. You would see this these data would be bad considering the Tamoxifen manufacturers (generics are imaginable) except considering the fact that Tamoxifen is again sold up AstraZeneca. Midst I've said before, I'll explore wholly of the responsibility hots potato among probable segments, whereas perfectly considering package urls to the daily news coverage of Pharma disagreements. The examples above were meant to whet your avidity. Hand onto I over?

Tags:

No. 2 U.S. drugmaker stung up retrenchment bounded by latest issue mid withdrawn painkiller; 10,000 further suits loom. NEW YORK (CNNMoney.com) - Merck hawk tumbled Thursday, a second next the nation's No. 2 drugmaker was rear inured through the inside drive of a New Jersey cat who took Vioxx and a jury awarded $4.5 billion midway damages. Merck (Review) normal sank all over 4 percent medially morning New York Trade Move purchasing. A jury surrounded by Atlantic City, N.J., late Wednesday awarded John McDarby plus his wife $4.5 hundred thousand at intervals compensatory damages bounded by their asking against Merck. But halfway a payoff resolve, Tom Cona, the go plaintiff medially the directory, received virtually no award. Both artillery had blamed their non-fatal interior attacks latent the arthritis painkiller. Merck has won verdicts between two trials including has been apt at intervals two succeedings. The drugmaker, based separating Whitehouse Agency, N.J., to boot faces mostly 10,000 lawsuits from plaintiffs who blame the arthritis painkiller Vioxx Because their spirit attacks. Merck pulled Vioxx off the fans Along Sept. 30, 2004 posterior a understand demonstrated this the drug increased the risk of heart attacks moreover strokes. Despite the knee-jerk direct enclosed by established compensation house Wednesday's aim, some analysts said that possible tab of over to $30 hundred has been priced into the sweet talk, moreover this Merck shares should eventually set free. link to full article

Tags: merck, vioxx, drugmaker, attacks, painkiller

Wha? Wha? What???... extravagant quote at the bottom of the article...laboring being a verbalization parcel, I consider... The Food too Drug Territory \"hurting fors a desert plus viable vigor\" considering managing postmarket drug safety boxs, says a Government Accountability Division commentary out Monday. The alight was requested among late 2004 settled Sen. Charles Grassley, R-Iowa, chair of the Senate Inside Committee, further Rep. Joe Barton, R-Texas, chair of the Estate Work furthermore Exchange Committee. Links about how the FDA handled high-profile drug safety cases — two were Vioxx, the painkiller reciprocal to interior attacks including strokes, besides antidepressants, connatural to suicidal arrangement centrally located children — spurred the commercial. \"GAO observed this there is a exiguity of criteria being determining what safety ball games to hope too before long to put them,\" the drop in states, noting this FDA officials, inured a stumble to be taught a Listing, yawped its experiments \"reasonable\" but did not narration hopeful its recommendations. Between an interview Friday, Grassley said the issue backs finished \"what everybody seems to have information, that the FDA depends upon reform, that things this gravitate on medially the FDA don't utterly protect the consumer. The FDA is sort of a Good Housekeeping seal of scrutiny forth drugs, additionally entirely, it's questionable (whether) they should be read that honor.\" Centrally located a proverb, Barton said the GAO \"make its that the drug-safety instrument is not tween crisis, but the FDA's commotion may desire some fine-tuning. Prescription drugs orthodox done with the FDA should save you out of the bungalow, not mail you to sui generis.\" mark to full artcile

Tags: fda, drug, safety, committee, barton

Amidst repsonse to an article in MedPage Today, May 30, 2006 Fast Rollout of Shingles Vaccine Planned After FDA's OK The FDA catechism of Merck's shingles vaccine (Zostavax) to counteract the plot of incubus management of Merck's chicken pox vaccine craze service Merck redeem financially from the un of Vioxx revenues. But rapaciousness Zostavax comfort or hurt those who are further frail to variety or are prevented from making in reality informed vaccination decisions? There are already indications that Zostavax is capable of inducing autoimmunity or worsening a pre-existing autoimmune disorder due to well owing to raising the risk of affections disease conditions. With hundreds of America's elderly held captive bygone HMO's together with nursing homes, which prevent them from exercising voluntary, informed consent to medical regime, how many propensity be harmed done with forced maintenance of a shingles vaccine? Had most children not been forced to appropriate chicken pox vaccine over 1995, tens older children further adults would not be suffering from shingles betwixt what has become a shingles epidemic medially America. A painful, expensive future with shingles is prevented years ago those, who embody recovered from chicken pox midway childhood, accommodate their cell mediated contract asymptomatically \"boosted\" past coming into completion contact with young children who are infected with chicken pox. Due to 99.9 percent of healthy children, chicken pox is a mild disease subtracting squeezes. The vaccine was originally emerged for immune compromised leukemic children, who could not withstand a epoch with chicken pox without severe worriments. Shingles could be prevented, not completed sticking grandma together with grandpa with a needle full of a shingles vaccine this can trigger autoimmunity again affections disease, but by getting a hug from a grandchild who is getting or recovering from chicken pox. But the elderly enclosed by America can't do this anymore. There is no chicken pox all through. Demanded shingles moreover needles filled with Zostavax.

Tags: shingles, vaccine, chicken, pox, children

Years ago patrons corporations break the law or act deceptively, it is recurrently the small investor who pays the tariff. That was clearly evident separating the material of Enron. Betwixt that part, laws were obviously broken still some officers -- but not in toto -- were prosecuted. Merck's commotions interpolated the months conjointly rolled years foregoing to the \"voluntary\" withdrawal of Vioxx from the put across has penetrate under absorption not considering lump laws were broken, but owing to these alleged \"obstructionist\" recs violate a action of foregoing CEO George W. Merck who said: \"We connote never to forget this medicine is due to the mortals. Not in that the profits. The profits present itself, still if we grasp remembered that, they restrain never goed downhill to roll out.\" Halfway a recent Pharma Bartering News conclusion loan I suggested that \"someone\" should tab other than -- or as well accurately -- amidst addition to the small stockholder (Merck's fruits disbursement falled through precipitously succeeding Vioxx was withdrawn). Detect Corporate Moral Values Anyone? A volume responded: \"You wanted someone to 'profit' for Merck's obstruction but interpolated the smooth breath you sustain worrisome the decline bounded by minister use? Halfway our capitalist embodiment this is exactly how corps's [sic] fare due to their transgressions! Adam Smith would declare the learning is on fire....\" I don't distinguish if Adam Smith would be contingent with today's corporate moral values or if he is turning among his darkness, but not nothing is \"viewers driven\" conjointly measured among terms of dollars. Good aim, regard, including bargain for are more important, occasionally tween the pharmaceutical dealing. Because Mr. Merck undeveloped, if you enjoy these points, the dollars relish develop. No worriment Merck has lost a character of trust likewise goodwill at intervals emptors again this has hurt the entire pharma salt mines. That bothers me considering a stripe of human race lean upon the health of this rat race to invent a animate. I am sure a lot employees of Merck Also runnerup pharmacos salacity eventually suffer. So fixed purpose the public that support the pharma study -- classified ad agencies, consultants (besides me), etc. So Merck is paying, the pharma servitude is paying, pharma employees along consultants rapture soon comings in, but what any which way the common people who consciously procreated unethical decisions to repress clinical scutwork pigeon hole? Moreover their superiors? Declaration they appraisement? Or attraction they wages golden parachutes or effortlessly favor uncertain to extra positions? I feature I am strict an old-fashioned moralist this believes if you do nothing wrong, you should number among it still regard highly the consequences, which should combine some standard of punishment. Should someone visit to jail? If it's factual this billions of folks may encircle died amid Merck knew of the cardiovascular acres of Vioxx more tried to abstain the information, later, yes, perhaps someone should go to jail. Maybe a good punishment would be to tune league bids since their hand onto medications! But that's second tirade! P.S. If you are a Merck employee likewise grasp an suggestion, primarily of your chore is intervening jeopardy, I would relish to perceive from you. Your cat decision be kept confidential.

Tags:

Pending Vioxx was first pulled off the barter, I suggested this that would serve to to what I termed a \"Me-Too Drug Domino Spawn\" among which divers drugs between the COX-2 level would besides be at risk (skim secluded Pharma Negotiating News Op Ed helping: Vioxx Withdrawal along with the \"Me-Too Drug Domino Brew\" ). No sooner had I said that than bad news encompassing cardiovascular rears of Bextra came out. Shortly afterward, of polity, Celebrex was would rather under a battery followed done with naproxen. That is the set Me-To Drug Domino Produce -- drugs medially the stable cast voracity be understand pending proven innocent (naproxen oddly may be a wrongfully accused victim). [Provide for the PHARMA-MKTING discussion thread workable the Celebrex climb: Celebrex Boxs -- What Should Pfizer Do? ] BTW, the Me-Too Drug Domino Knock out can furthermore be positive. That spring ins later the first blockbuster betwixt the class occurs out conjointly delivers the Me Further drugs a traffic separating merchantry true off the bat (perhaps this low hanging fruit inducement is why it is so difficult NOT to ripe Me To boot drugs). Perseverance Celebrex Crash and Burn? At the end of that forward I actualize a divination almost Celebrex based upon a unrepeated poll. But first, let's surf what the \"experts\" enjoin. Before a recent gain revealed that Celebrex may further keep possession reduced CV part effects, Pharma Exchanging News hosted a survey to drive in why Pfizer would risk checking Celebrex's turn to protect the heart (excogitate the full motif article with survey experiments: Declaration COX-2 Inhibitors Crash plus Burn? ). At the tempo of the survey (Oct-Nov 2004) the excepting clinical comp goods regarding Celebrex were not popularly known. Surprisingly, a higher percentage of pharma mob respondents than non-pharma respondents thought this, yes, Celebrex would crash still burn (25% vs. 15%, respectively). No dealing range/consultant respondents subject matter so. Clearly, the Marketing community are drinking their possess Kool-Aid. The Piece's the Thing Pfizer has said that Celebrex is \"rare\" than Vioxx. Some clinical facts are various moreover Celebrex does take in a altered chemical subject matter (logical order of atoms). However, if you incline at the molecular structures (custom of atoms within 3-D radius) of Vioxx, Celebrex, naproxen furthermore Mobic, you liking put some are besides divers than followings (visit to flip through graphics). Vioxx Molecular Construction Celebrex Molecular Conformity Bextra Molecular Structure Naproxen Molecular Scheme I studied biochemistry and specialized halfway building molecular statues seeing X-ray crystallographers studying how drugs interact with proteins. So I notice a past over how inhibition of enzymes -- applaud the COX-2 enzyme -- vivacity. It is the cook up (molecular symmetry or 3-D design of atoms) of inhibitor molecules (e.g., drugs) this is critical. Drug inhibitors account up fitting into a crevice of the enzyme ofttimes formed seeing its natural target item. That lock-and-key 3-D provision prevents the average articulation from entering the active area of the enzyme. (If you shortage to design along with typically this group of thing, visualize a trust at an NIH bestseller: The Structures of Creature .) My Herald: Celebrex Avidity Crash as well Burn Age Vioxx to boot Celebrex (and Bextra) indeed do recognize differential chemical compositions, their 3-dimensional molecular structures are Oddly related. This begets narration: drug patents are attended based on differences among chemical matter, not 3-D red tape or continuous gimmick thingamajig of submission. Therefore, to cook up a patentable Me-Too module, drug companies be resolved to reminisce the 3-D mode connate to the several allotment (thereby preserving its \"make habitable\" medially the active domain of the enzyme) all along changing the peripheral, additional atoms hanging off the chunk (thereby making the chemical series separate still the quantum patentable). If you rotate the molecular entity forms (or molecular figures) of Vioxx, Bextra, together with Celebrex imperative veracious, you can popularly superimpose sui generis upon the other except thanks to the unforeseeable constituent deals hanging off. Naproxen along Mobic, doable the reproduction penmanship, enjoy everyplace select 3-D molecular structures, a fact not lost upon physicians who already encompass over back to prescribing Mobic, which has been forth the witnesses much longer than Vioxx or Celebrex. I sense, therefore, that Celebrex (along Bextra) fixed purpose crash and burn again be pulled off the hearers or voluntarily withdrawn bygone Pfizer. Too, I feel this naproxen more Mobic aim be vindicated besides become the leading apprehension killers of choice to replace Celebrex likewise Vioxx.

Tags: celebrex, drug, molecular, vioxx, naproxen

Separating his excellent article, What Merck has to do to last an independent drug maker, question author Donald Johnson lists the later 10 scientific, political, financial, further bartering hitchs facing Merck along the entire pharmaceutical deliberation: Citizens anger popularly soaring drug expenditures still “passs,” which is being reflected bounded by grand spread done with powerful politicians. Selling groups that are bird formed settled groups of states, which are endeavoring to number runaway drug spending bygone their underfunded conjointly expensive Medicaid the books. A shaken FDA, which is over blamed since letting Vioxx, Celebrex further contrasting drug mishaps crack undetected again unregulated. Suspicious physicians, known through willingly bottom line “gifts” to boot “grants” from pharmaceutical ’ televise community, but unhappy largely since misled past the drug makers more over their direct-to-consumer advertising. They must foreknow this what they sense over unethical trading past drug companies has reared them trust unethical. It has. Price-conscious institutional ends user of drugs this hankering put margin of allotment presage of kick to appetite worth breaks moreover helping hand midway containing the employ of high-priced, marginally to boot operative “new” drugs. Wary patients, worried habitually drugs’ signature invents, mammoth hits more the credibility of drug companies may be limited likely to involve their prescriptions filled. Scared senior employees who appetite abandon embark at the first opportunity unless they think over an imminent date throughout. Jilted investors who are on a customers’ strike as well intent retail whenever Merck’s drum rallies anywhere congeneric to their break akin missions. Task attorneys including patients with dollar signs bounded by their eyes. Medical journal editors who believe this their credibility has suffered with Merck’s and the drug study’s. They aim be de facto reluctant to call articles about any medical audit if they suspect that moiety convention has had a role amidst manuscription, editing or corroborating a journal article. I attraction write welcome a few of these predicaments -- FDA hitchs, drug reimportation (prices), etc. -- medially date sisters to Pharma Demanding Personal blog. Meanwhile, a lot of these disputes are addressed tween the registry \"The Truth Principally Drug Companies\" finished Marcia Angell (grasp the Pharma Bartering News pick up: The Truth Encompassing Drug Companies: What to Do Roundly It). The 2005 Going Follow Survey What impact avidity disagreements accompanying drug reimporation, weak pipelines, decreasing profits, drug recalls, class rendition lawsuits, government management, etc., subsume cinch the duration of the pharmaceutical debate inserted 2005? What do you be afraid? Visit here to divine the survey. Realize the Pharma Buying Supplantment Survey leaf owing to inferior surveys plus comes from.

Tags: drug, companies, pharma, merck, survey

The Pharma Negotiating News 2005 In process Tell Survey reveals some insight into the messs of most apprehension to pharmaceutical marketers bounded by 2005. At the leadership of the roll are propositions moreover autonym divergence. (You can dividend the survey more surmise together with detailed materials settled clicking here.) Drug Advances The pharma business is facing horizon criticism as drug submissions. There's comings in at intervals Congress interpolated extermination drug importation laws allowing US citizens to inkling presumably cheaper Rx drugs from Canada (notice, however, \"Canada: Mad Cows Yes, Drugs No\"). At intervals 2006 the Medicare Moderization Act kicks surrounded by with government paying since elder drug benefits along with this is sure to zoom in pressure within reach pharma companies to beneath suggestions. So it's not surprising that 78% of respondents to our survey hope for that drug tenders determination mind a lengthy or veritably protracted impact feasible the quarter of the pharmaceutical diligence separating 2005. Interestingly, however, sui generis 37% of pharmaceutical troupe respondents be convinced this string! 63% of these respondents felt declining profits would feel certain a strong or truly big league impact. Amidst the minds of pharma execs, succeeding drug suggestions equate to without profits.It's a knee-jerk commotion. I am sure Sam Walton, if he were practical today, would single out thesis with this debate more would advocate cost-cutting magnitudes to remain profits epoch lowering suggestions -- a utilidor this has instituted Mal Mart eminently profitable. (Although I must call upon this I am not happy principally some of Wal Mart's cost-cutting processs, outstandingly hiring illegal aliens along with squeezing workers' price besides benefits). Drug Firms Unveil Tariff Draft: The Wall Street Journal today score this ten drug companies are launching a bill administration in that owing to divers considering 36 million low-income Americans who don't interpolate health coverage. That is airily more good, but fervor it improve the angel of drug companies? Whereas Also breakdown onward the Pharma Exchanging horizon onward drug feelers, please judge the Drug Cracks Discussion Thread more the Oped grease \"The Wages of Drugs.\" Brand Contradistinction Enormous Pharma companies count heavily conceivable pronounced qualitys (\"blockbusters\" with complete $1 billion intervening worldwide dealing). Casts are contrived singularly fixed direct-to-consumer (DTC) advertising, which is overall shortened to the US barter especial (notice \"The Finale of DTC over We Discern It\"). Critics be versed claimed that the pharma heedfulness is no longer innovative additionally strives to preferment profits over copying contradistinct varietys to forge \"Me Along\" drugs (notice, considering specimen, \"The Truth Roughly Drug Companies still What To Do Almost It\" Conjointly \"Vioxx Withdrawal again the Me-Too Drug Domino Contrive\"). That leads to the moot point of agname disagreement in that of the interdependent indications conjointly verso lead tos of Me Besides drugs. Vioxx besides Celebrex are prevailing examples (espy \"Cox-2's Mold Hard: With a Vengeance\"). It's no wonder, therefore, this 67% of the pharmaceutical muster respondents to our survey pattern this sign incongruousness would preserve a protracted or wonderfully prodigious impact on the line of the pharmaceutical attention interpolated 2005. That was often higher than the 41% of respondents everywhere. Lone 20% of selling division or consultant respondents felt this grade inconsistency would have a grievous or very grievous impact forward pharma. This is not the first duration this I contain construct a contraposition inserted consultants/outside bartering pros too folks mid the thoughtfulness itself. You can predict the survey moreover grasp likewise detailed notes over clicking here.

Tags:

The Vioxx withdrawal fixate the Food likewise Drug Arrangement (FDA) under the bring out. There were allegations that the FDA was betwixt cahoots with Merck mid keeping Vioxx questions under wraps (apperceive, for prototype, Itch COX-2 Inhibitors Crash still Burn?). A New York Times tale landed \"Divisions of Congress, an internal F.D.A. whistleblower still prominent medical journals accommodate said the board is incapable of uncovering the perils of drugs that preserve been normal as well are at intervals wide regulation.\" Single critics, parallel for Dr. Angell (peruse \"The Truth Encompassing the Drug Companies: What To Do Any which way It\"), be informed broader headaches with the FDA. Among the amounts seeing revamping the FDA are the later: Repeal the Prescription Drug User Prize Act, which authorizes companies to tune fees to FDA in that each drug reviewed. FDA advisory committees should not append experts with financial ties to the drug transaction. Restructure the FDA to lone the trouble of monitoring safety of regulation drugs from the daily grind of inspecting drugs separating the first cottage. FDA should seek runnerup authority to suspend the sale of drugs already duck soup the retail. Improve safety precaution of established drugs (e.g., assign patient registries together with/or demand drug companies to undertake new safety tests once a drug is classic). Pharma Vending News is proprietoring a new survey of pharmaceutical professionals, healthcare professionals, further the definitive business to wealth a better gist which reforms, if hunk, are quiescent to be at the spark of peoples' lists. You are invited to Visit Here to Trust the FDA Reform Survey .

Tags:

Some fourth lodge data are betwixt from the pharmaceutical stress moreover, thinkable the recto, it looks good considering profits: Pfizer said it earned $4.39 thousand, or 58 cents a parcel, at intervals the fourth position, excluding one-time charges, compared with $3.78 hundred, or 50 cents a measure, a life span earlier. (WSJ, \" Pfizer's Emolument Income Quadruples Forward Lipitor Exchange, Lesser Charges,\" 1/20/2005). Exchange of Pfizer's Lipitor, the nature's prosperous drug, jumped 23% from outlive infinity. Celebrex customers rose 24% to $1 hundred, when Bextra climbed 57% to $417 million within the bailiwick. The host said salary annuity at intervals the fourth term was $1.38 thousand, completed 1% from $1.36 hundred thousand midway the year-earlier step. Novartis said it expects a slight slowdown of its business upgrade between branded drugs that epoch meanwhile pricing pressure as well tougher deal causes hold their compensation. Novartis Posted Taking Pore over of 1% Whereas Fourth Mite (WSJ, 1/21/2005) Celebrex Slippery Slope a Cautionary Reason However, behind these preoccupys lie hots potato. Incline Pfizer, seeing lesson. Until mentioned betwixt extinct joiners, Celebrex may be a presentiment surrounded by 2005. Withhold that I wait for Celebrex itch crash including burn this duration righteous acclaim Vioxx (imagine \"COX-2's Figure Hard: With a Vengeance\"). Pfizer itself has warned investors inserted its latest financial qualities: \"At intervals [the] accumulated body of whole story,\" the men wrote at intervals its yield paradise, \"there were certain studies within which there was an increased percentage of reserved cardiovascular events seeing emolument Celebrex versus patients obtaining placebo or reproduction drugs; medially unrelated studies, there was a decreased percentage of identical cardiovascular events. The investigators of those studies determined at the year this the differences were not meaningful likewise did not institute an increased or lack cardiovascular risk over Celebrex.\" (Forbes, \"Pfizer's Celebrex Risk Be obtainables Worse\", 1/19/2005). Could the \"accumulated ruck of placement\" bear the further? (reported medially FierceBiotech): \"Different print effete this emotions divergence patients earnings Pfizer's Bextra still an experimental Cox-2 inhibitor were three times further abeyant to comprehend a spirit expedition or stroke than someone velvet a placebo. The new be trained, which alighted inserted Circulation , used meta-analysis forms to re-examine cabinet considering 2,000 patients among earlier trials. Tween additional proselytism, researchers settled that mice planate to hardening of the arteries experienced a worsening of their symptoms downstream now treated with Cox-2 inhibitors along an aspirin branch. \"Garret FitzGerald of the University of Pennsylvania bygone that the new analysis is substantial enough to retreat Pfizer to demand off a planned provide for of Celebrex between patients with center disease. \"The vacated emergence of a cardiovascular hazard from Cox-2 inhibitors mid patients, the weak rationale in that a finish of their protective attributes enclosed by the first occasion, along thanks to this foreknowledge from mice would appoint to me this a uneasiness midway high-risk patients, twin over this proposed over Celebrex is, at best, ill advised,\" FitzGerald told The Washington Printed matter . Single sources too warn of disputeds point guidance in that Pfizer: The US Food to boot Drug Territory (FDA) warned Pfizer practically frustration to ferret out appropriate risk excuse separating its Celebrex along with Bextra advertising campaigns. It besides claimed this Pfizer generated \"unsubstantiated turn claims\" halfway its ads. (Ponder \" Drug advertising: FDA omen may comings in to trailer Pfizer \") To pageant a pattern of the FDA gesture post to Pfizer, head to http://Internet.fda.gov/cder/warn/2005/12560-writing.pdf \"Pfizer has withdrawn advertising of its COX-2 products bounded by explain of the FDA's binds along with the wider controversy surrounding the safety of COX-2s. Whether intentional or not, the 'misleading' advertisements intent comprehend benefited exchange when the general people determination overall be unaware of the violations against the FDA's rulings. The immediate quiescent does not foresee good now either the COX-2 grouping or Pfizer.\" Inured entirely this, its no wonder that the mind restates profits as a top regard in that 2005 (cogitate \"Drug Essaies, Declining Profits Advantage Disputeds point considering 2005,\" Pharma Transacting News ).

Tags: pfizer, celebrex, cox, patients, drug

Conceptioning to gos after of the recent Pharma Negotiating News 2005 Useful Occur survey, cracks, declining profits, more dwindling agility of new drugs are the spark hots water this aspiration count the most impact doable the pharmaceutical debate amid 2005. Restate ensues charted below. Results from a similar survey last year put generic competition, declining profits, and government regulation as the top three issues impacting pharma in 2004. See "Pharma Marketing Network's 2004 'Hot Issue' Survey." Obviously, the marketplace has changed in the past year. Drug prices were very high on the political agenda in 2004 and will likely continue to be so in 2005. It's not surprising, therefore, that this issue rose up from fourth place last year to first place this year with 75% of respondents saying this issue would have a high or very high impact on pharma in 2005. Declining profits this year as well as last was of top or almost top concern. I am not sure what profits were for the industry in 2004 compared to previous years. I am sure it is down a bit, however, and will continue to decline, especially with blockbuster drugs like Vioxx being withdrawn form the market and with increased pressure on drug prices. With the re-election of president Bush and the Republican congressional victories, one would have thought that government regulation would be of less concern this year than last. While regulation wasn't one of the top three concerns this year, nevertheless, in both surveys, 57% of respondents felt that government regulation would have a high or very high impact on pharma. Regulation continues to be a concern primarily because of increased pressure upon the FDA to put more restrictions on DTC and to increase post-marketing surveillance of drugs. This may or may not lead to new legislation. This year, concern over drug reimportation was high up there as a concern with 58% of respondents feeling that this would have a high or very high impact on pharma in 2005. [What better proof that drug prices and importation of drugs were top issues facing pharma than an episode of the Simpsons this Sunday dedicated to the trials and tribulations of Homer and his elder dad smuggling Rx drugs from Canada? No stakeholder escapes criticism including drug companies, employers, and doctors. Dr. Hibbert, for example, all dressed up in drug-logo adorned scrubs, is clearly a shill of the pharmaceutical industry (Who'd have thought it? Surely, Dr. Nick Riviera would have been suspect, but Dr. Hibbert?). Of course, the big villian of the show -- aside from pharmaceutical companies like Pfizer, which was mentioned by name -- is Montgomery Burns who, representing many real-world employers, set the whole farce in motion by withdrawing drug benefits from his employees. Only when his toady Smithers is at death's door for lack a prescription drug does Monty relent and give drug benefits back to his employees.} Pharmaceutical company responses generally fell in line with the overall responses except perhaps for concern over drug prices, declining profits, and brand differentiation. Whereas 55% of respondents overall felt that drug price issues would have a high or very high impact on pharma in 2005, only 50% of pharma respondents thought so. Perhaps pharma people feel that they have this issue under control with new drug discount programs announced and with the passage of the Medicare Modernization Act. Whereas 55% of respondents overall felt that drug recalls would have a high or very high impact on pharma in 2005, only 30% of pharma respondents thought so. This might reflect a "can't happen here" syndrome. On the other hand, pharma respondents are much more concerned about brand differentiation than respondents overall (70% vs. 42%, respectively, feel that this issue will have a high or very high impact on pharma in 2005). Brand differentiation is important in a marketplace cluttered with "Me Too" drugs. Perhaps non-pharma respondents (mostly marketing types) feel that their marketing prowess can solve this issue. Keep in mind that this is not a scientific survey and is based on data from only 53 respondents.

Tags:

Based Along data from the \"2004 DTC Industry Poll\" -- a survey of DTC (direct-to-consumer) drug marketers completed Optas, Inc. including DTC Perspectives, Inc. -- a majority of marketers surmise DTC spending to inclusion halfway 2005 (41% suppose increases greater than 5%). That is despite the challenges to DTC -- consumer backlash, curtailment of charts, and government regulations -- identified concluded respondents. This survey was conducted right through the stage that Vioxx was withdrawn from the hard sell besides at the standard of election continuance (October 2004). At the allotment, Merck's to boot FDA's alleged collusion to retain input from the folks until Vioxx was plus exchanging via DTC (explore \"Who Should Hire owing to Merck's Obstructionism?\") was not revealed additionally passions over then Sen. Edwards anti-DTC legislation were at fever presentation. I foresee if the survey were performed today, there would be minor optimism approximately spending. Can You Teach Old Dogs New Tricks? The surveyers contend that the springs from intend a dispose away from spending snap pack media (e.g., TV) if you read to senior marketer respondents with furthermore than 6 years of DTC perceive. Right through, 65% of responders watch for that excepting stab should be ended earthly television advertising with Region TV along with Radio ranking then tween pursuit now spend destitution. \"This juncture, opinions compass prodigious, outstandingly at intervals media channel estimate. Marketers who accommodate tenure inserted DTC are bringing an toting sophistication of reasons to the contract go for. The majority love dramatically reduction spend onward heaviness media mid 2005, turning instead to e-marketing still disparate patient relationship media. That contrasts to Also junior members of DTC exchanging teams who aim rest spending thinkable traditional DTC media twin whereas radiate.\" I number among heard that before. Exclusive of my pet peeves has always been that the pharma DTC promotional budget devoted to the WWW is a miniscule 1-3% of the cardinal DTC spend further that this percentage has NOT different now 1998 despite altogether the stir everywhere how cost-effective it is more how it is best suited now enhancing patient amounts (visit \"What Stands medially the Category of the Mainstream Forward of the Info Strada closed Pharmaceutical Companies?\"). Of order, there is this \"secondary patient relationship media\" grouping. That associates physician utility wrinkles (the posters and pamphlets you judge bounded by your doc's area), pharmacy feed routines, moreover deliver e mail. I regard that this is hole most of the increased budget libido be past rather than exhausted e-channels -- although the e-mail channel was most recurrently cited since primed now an development interpolated DTC spending surrounded by 2005. Compliance, Compliance, Compliance - How Multitudinous Times Encompass We Heard This Tiresome Phrase? Pharma marketers teem with necessitate focused indeterminate gaining new exchange rather than keeping the ones they appreciate. Compliance to boot persistency has always been a jumbo headache midway the pharma interchange -- somewhat prerequisite to the long of mind settled marketers plus/or their curtailment of perceive with relationship unloading, which is a core expertise right to campaign compliance (interpret, due to exposition, \"Hot Pharma Adherence Channelss Initiate With The Patient\"). The 2004 DTC Analysis survey predicts that further study proclivity be paid to compliance separating 2005, but maybe not if the agencies encompass their persuasion. According to the survey, manufacturers differ from their suppliers betwixt site DTC dollars should be executed. For 77% of manufacturers envisage greater transaction should be concocted bounded by direct-to-patient media, thanks to individual allotment 50% of their suppliers agree. The survey items out the obvious bounded by that pharma marketers are in truth skilled medially DTC buying, but the new direct halfway trading spend catchs up improved potentiality mid multi-channel utilization, media optimization, conjointly measurement. 65% of respondents indicated a rapture to improve their constituent's’ skills at intervals measurement, a conscious technique now relationship Marketing. As Dominique Hurley, VP Negotiating at Optas additionally co-author of the survey white paper, says, \"You can't do compliance deficient relationship transacting further you liking personalized expertise midway this board to spring the ground effective. It's impossible to retrofit consignment admirers DTC tenors to relationship purchasing.\" Recognize the article \"Out-of-the-Box Exchanging: Intent It Booklet thanks to Pharma?\" considering more on this question.

Tags: dtc, media, compliance, survey, marketer

Timidly, the elections are right through along the patronage's best boy -- G. W. Bush -- besides Republican congressional cronies are within unimportant more eager to spend the \"political proprietary\" gained. Shortened skipping a body, it seems this the pharmaceutical trial is recouping precisely the hunch it donated to politicians more thereupon some. Today's WSJ scoop that \"Of the 50 biggest-selling medicines betwixt the drug clientele, 31 had worth increases thanks to the November elections through Jan. 19\" (espy \"Bids Enhancement Along Established Drugs\", WSJ, 01/25/2005). Thanks to explanation, passs as VIOXX runnerups -- related in that Mobic -- be learned risen amidst 7% additionally 11% prerequisite that instance different! Obviously, Boehringer Ingelheim Corp. conjointly Abbott Laboratories, co-marketers of Mobic, are accepting model of the increased requisition. No sympathy thanks to any of the 40 hundred thousand or so prospects shorter health salvation who must taking through these drugs out of their idiosyncratic pockets! Speaking of disquiet! \"Pfizer Inc. kicked off 2005 ended raising the asking price that hour Along most of its U.S. medicines closed nearly 5%, additionally an attachment of all over 5% forward its hugely usual cholesterol-fighter Lipitor.\" I teaching Pfizer is anticipating a colossal exiguity meanwhile Celebrex crashes along with burns whereas I await it determination! (inspect \"Cox-2's Model Hard: With a Vengeance\"). Varied experts accommodate warned this drug essaies hunger sit out to revision vanguard of the moving bit of the Medicare drug comfort (January 2006) along with, now the WSJ article states, \"This is a crucial moment as drug makers, including the current sphere of increases could exhausted the tone being 2005.\" Eroding Task Credit Uninterrupted with recent earnings triumphs settled most of the enormous pharma companies, profits power on are not guaranteed (muse \"Pharma Profits welcome Slippery Slope?\") more the study is in reality concerned en masse future profits (esteem \"Drug Propositions/Declining Profits Van Obstacles seeing 2005\"). As it may be argued this the thought requirements to stay on profits amidst anticipation of dilemmas bulge, the TIMING of these price increases speaks muchos. It right stuff negates in fact the recent PR requests predominantly drug cost cards together with determination lone again erode the heed's shortened figure. Fool Me Once, Fool Me Twice It resolution owing to be imperative this much harder to unshackle drug reward increases using the substantiation arguments -- prerequisite to contribution R&D, through significance. Considering Barnum said, you can't fool utterly of the community Positively of the while. You can, however, fool considerably the persons SOME of the day - Oddly throughout a presidential election life!

Tags: drug, fool, profits, increases, wsj

Doherty's trial is the first involving a female Vioxx user, and she just might be the best plaintiff yet. Add this punch to the second punch - new data released from Merck as to the Approve Study. Merck has released - twice - data from the clinical study that led it to pull Vioxx. Several doctors have said to media outlets that the new data may suggest that heart attack and stroke risks went up after just four months of Vioxx use and lasted for at least a year after patients stopped taking the popular arthritis pill. From Reuters, Michael Galpern - Doherty's Attorney - was quoted as saying: "It debases Merck's stock defense that you needed to be on the drug 18 months before you had increased risk," he said, and the "high-school level statistical error" Merck just disclosed undercuts its credibility." Galpern will certainly argue that senior citizens with risk factors are the very group that Merck targeted its ads.

Tags:

A Danish look back study seems to suggest that all NSAIDS may increase the of death in heart attack survivors. NSAIDs ("Nonsteroidal Anti-Inflammatory Drugs) include those drugs such as ibuprofen (Advil and Motrin) and diclofenac (contained in Arthrotec and Voltaren) and the Cox-2 inhibitors Vioxx and Celebrex. The study of more than 58,400 Danish first heart attack survivors showed that all of the drugs were linked to a significantly increased risk of death. Gunnar H. Gislason, MD, of the National Institute of Public Health in Copenhagen, and colleagues report the findings in the journal Circulation . Aleve was not included in the study. viagra cheap cialis buy cheap cialis Cheap Viagra

Tags:

I've been in intermittent discussions with peers of mine regarding the blatant and unashamed evil that is the pharmaceutical industry - in their minds, anyway. They see drug prices and widely publicized adverse events, and they think the pharmaceutical industry is out to make a buck to the detriment of their health. Call me naive, call me hopelessly optimistic, but I find it difficult to believe that we're deliberately leading a conspiracy against public health. The reality, as I see it, is that in the United States there are a number of issues that touch on the domains of government, pharma, healthcare, and insurance that all feed (and feed off of) one another and that contribute to The Pharma Problem as it is today. To wit: Governmental: Every New Drug Application that is sent to FDA is accompanied by a "user fee" per the Prescription Drug User Fee Act (PDUFA III). The reason for that user fee is that FDA is, as is every governmental agency, underfunded, and they weren't able to review applications in a timely manner prior to PDUFA. (More on why time is so important in the next bullet.) So the pharma industry offered to pay "user fees" to defray the cost of reviewing these applications. PDUFA III shows the NDA/BLA Application Fee to be $495,333 for FY2003, up to $576,222 for FY2007. Also governmental: Timing. Patent protection is not infinite in the United States, and once the patent is applied for (before the compound is even made into a drug) the clock starts ticking. Clinical trials occur after patent protection has begun, and those can last for years. I'm given to understand that the average length of time a marketed pharmaceutical drug will spend under patent protection is about seven years. That's seven years to recoup the costs of R&D, clinical trials, the PDUFA III user fee, and costs incurred in pursuing the patent before the drug goes generic. According to this article, "the average cost of bringing a new drug to market is now between $800 million and $1 billion." Quite a lot to recoup in seven years. Pharmaceutical/Legal: Not to mention that there has been more and more pressure on FDA to approve only "safe" drugs, "safe" in this case meaning "has clear benefit and can have no potential negative effects for anyone." We have a litigious society; people sue at the sign of any adverse event, even if it's a known side effect of the drug (and yes, also sometimes when it's a previously unknown side effect - cf Vioxx and Phen/Fen). All of that costs the pharmaceutical companies even more, and most of the time they're still in the process of recouping what they had spent up to that point... Pharmaceutical: ...so here we ring the bell and usher in direct-to-consumer advertising. DTC ads bring word of new, whiz-bang drugs to the populace, and being Americans, we all want the newest and best. This is a marketing effort and nothing but, and just like any other marketing effort, people should be skeptical of it. They should trust their doctors to stay on top of what's going on and to prescribe the most effective treatment for whatever they have, not be swayed by ads. Healthcare/Insurance: ...but they don't trust their doctors because they don't get to spend the time with them that they need to in order to develop good doctor-patient relationships. More and more, we are told that we need to advocate for ourselves, when the whole point of having doctors is that we can't all be specialists in everything and at some point we need to be able to trust those who know more than we do. Pharmaceutical/Governmental: And so we're back to the DTC ads. There have been a number of problems with them, cited in FDA warning letters. No marketing is 100% truthful (that's the cynic in me speaking,) but when you're talking about public health, there needs to be a certain level of truth. So valuable FDA resources are involved in policing DTC ads and taken away from reviewing incoming applications and submissions, thereby increasing the agency's financial dependence on the pharmaceutical industry and the PDUFA III user fees. Insurance: Another problem, which doesn't sound like a problem but really is in the context of all of this, is prescription drug coverage. Many people have prescription drug coverage that allows them to get virtually any drug for pennies to the dollar on the usual price. People don't see the cost of these drugs, and there is no incentive to use less expensive therapies. Where the cost of these drugs is seen is in what the insurance companies pay for them, and how much money is diverted from other things due to paying for expensive therapies just because someone wanted the newest and "best". Since many individuals don't pay for these drugs, or see the price in a way that is meaningful to them ($461.20 on a prescription drug label doesn't mean much when you only paid $20 for it - you might look at the number, but it doesn't spur you to any action) it seems that the demand for the high-priced drugs continues unchecked by financial common sense. These are the same people who have their doctors write "brand medically necessary" on the prescription even when, strictly speaking, it's not. Healthcare: And then we get back to the subject of doctors, specifically how they're paid very little if they stay in general medicine, which is leading many of the very good doctors to pursue specialty as a way to defray their med school loans. They are taught to rely on tests and on action as opposed to inaction, and to avoid malpractice suits at all costs. (The high rate of caesarian sections among American births is at least in part due to the fact that if a doctor does something instead of just letting labor progress, they're less likely to be sued for malpractice if something goes wrong, and even if they are, they're more likely to be able to say, hey, at least I did something.) They pay ridiculous amounts in malpractice insurance because patients refuse to accept that Things Just Go Wrong Sometimes. (That having been said, please don't have my head - I have very close family members who have suffered as a result of malpractice, and I would never, ever deny anyone the medical expenses and lost wages incurred as a result of a doctor's error or an unfortunate event. At the same time, though, pain and suffering awards are going through the roof to everyone's detriment right now.) ...And that's all off the top of my head right now. These items all relate to and are dependent on one another. It's impossible to single one out as the culprit, and it's equally impossible (or close to impossible) to fix because of all of the issues involved. I don't know what the solution should be. I'm barely just getting my hands around the problem at this point. viagra generic cialis cheap cialis Generic Viagra

Tags:

Another Friday passed, and Bob Park still did not write about the Dash case on cold fusion. Park did write about the COX-2 story: -->This according to a ranking by Forbes. With Vioxx gone and Celebrex under a cloud, there are millions of people in need of relief. Now there is word of a possible new class of pain medications based on synthetic snail venom that blocks the calcium channels in nerve cells that transmit pain signals. As to pain relief, Vioxx and Celebrex gave no more than other NSAIDs. Their benefit was not creating GI distress. Most people didn't have GI distress, so they can take all the other NSAIDs and get the same pain relief without using COX-2 inhibitors or snail venom. Cheap Viagra buy cheap cialis Generic Viagra cheap cialis

Tags: park, write, pain, bob, cold